BTR Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

BTR Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$227K	Sell	545 -50	-8%	-$24.9K	0.04%	151
2022 Q2	$295K	Buy	595 +80	+16%	+$41.7K	0.04%	138
2022 Q1	$290K	Sell	515 -85	-14%	-$51.2K	0.04%	144
2021 Q4	$453K	Hold	600	–	–	0.05%	128
2021 Q3	$448K	Hold	600	–	–	0.06%	121
2021 Q2	$387K	Buy	600 +180	+43%	+$110K	0.05%	132
2021 Q1	$240K	Sell	420 -170	-29%	-$101K	0.03%	152
2020 Q4	$344K	Hold	590	–	–	0.05%	130
2020 Q3	$304K	Hold	590	–	–	0.05%	124
2020 Q2	$266K	Hold	590	–	–	0.05%	130
2020 Q1	$207K	Sell	590 -100	-14%	-$36.8K	0.05%	140
2019 Q4	$255K	Hold	690	–	–	0.04%	144
2019 Q3	$230K	Hold	690	–	–	0.04%	147
2019 Q2	$216K	Sell	690 -2,430	-78%	-$728K	0.04%	155
2019 Q1	$954K	Buy	3,120 +150	+5%	+$40.5K	0.18%	85
2018 Q4	$690K	Hold	2,970	–	–	0.15%	93
2018 Q3	$930K	Hold	2,970	–	–	0.16%	83
2018 Q2	$857K	Hold	2,970	–	–	0.17%	78
2018 Q1	$743K	Hold	2,970	–	–	0.15%	85
2017 Q4	$709K	Hold	2,970	–	–	0.14%	87
2017 Q3	$660K	Hold	2,970	–	–	0.13%	87
2017 Q2	$672K	Sell	2,970 -220	-7%	-$47.9K	0.14%	87
2017 Q1	$636K	Hold	3,190	–	–	0.13%	89
2016 Q4	$523K	Hold	3,190	–	–	0.12%	107
2016 Q3	$523K	Buy	+3,190	New	+$484K	0.12%	107

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BTR Capital Management's BIO Position: Q3 2022 in Review

BTR Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 8.4% in Q3 2022, selling an estimated $24.9K and leaving 545 shares worth $227K. The position accounts for 0.04% of the portfolio, ranked #151.

BTR Capital Management first reported a position in BIO in Q3 2016 and has held it in 25 quarters since. The position peaked at $954K in Q1 2019. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

BTR Capital Management held 545 shares of Bio-Rad Laboratories Class A worth $227K as of Q3 2022.
BTR Capital Management sold 50 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $24.9K.
Bio-Rad Laboratories Class A made up 0.04% of BTR Capital Management's portfolio in Q3 2022, its #151 holding.
BTR Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and has held it in 25 quarters since.
BTR Capital Management's Bio-Rad Laboratories Class A position peaked at $954K in Q1 2019.
485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on BTR Capital Management's 13F filing for Q3 2022, filed 12 Oct 2022.